Immune and metabolic interrelationships of psoriasis with comorbid states (literature review)
https://doi.org/10.25789/YMJ.2022.79.20
Abstract
Psoriasis is a polygenic disease in which chronic inflammation in the skin develops as a result of an interaction between genetic predisposing factors and environmental triggers. The self-sustaining inflammatory response of the skin coexists with autoimmune and autoinflammatory components. From an immunological point of view, psoriasis is characterized by profound changes, including sustained activation of the tumor necrosis factor alpha axis with interleukins 23 and 17 (TNF-α/IL-23/IL-17), as well as high expression of early pro-inflammatory cytokines.
The study of the pathogenesis of psoriasis is still relevant. Numerous studies have established that concomitant ("comorbid") diseases are associated with psoriasis, which may be due to individual links in the pathogenesis of the underlying disease, including through immuno-metabolic disorders.
The purpose of this review was to analyze current data on the relationship between psoriasis and comorbid conditions. The review presents new data on comorbid associations of psoriasis with metabolic syndrome, cardiovascular diseases, intestinal dysbiosis, and other pathologies.
The object of the study was publicly available scientific information, the search for which was carried out in the databases: PubMed, Medline, Scopus, Web of Science, RSCI, without language restrictions. An analysis of the literature data showed that psoriasis should be considered as a systemic inflammatory condition underlying comorbid associations. The pathogenesis of metabolic disorders in psoriasis is associated with constitutionally determined immune hyperreactivity. In turn, the developed metabolic abnormalities increase immune inflammation due to newly formed molecular patterns of dangers (DAMPs). Promising in understanding the causes of the formation of comorbid conditions and diseases in psoriasis is the study of general metabolic parameters, which will expand the understanding of the mechanisms of formation of comorbidity in psoriasis. In addition, this will allow the development of complex pathogenetic therapy, taking into account the correction of violations of metabolic processes in the body of patients. The analysis of scientific information shows that the systemic nature of psoriasis implies a personalized approach to its diagnosis and treatment, taking into account comorbid (comorbid) conditions.
About the Authors
E. L. Romanova
Kemerovo State University
Russian Federation
Russian Federation
Romanova Elizaveta Leonidovna – post-graduate student
650000, Kemerovo, st. Krasnaya d.6
A. V. Shabaldin
Kemerovo State University
Russian Federation
Russian Federation
Shabaldin Andrey Vladimirovich – Doctor of Medical Sciences, Professor of the Department of Genetics and Fundamental Medicine
650000, Kemerovo, st. Krasnaya d.6
E. V. Shabaldina
Chief Physician of Modern Medical Technologies LLC
Russian Federation
Russian Federation
Shabaldina Elena Viktorovna – Doctor of Medical Sciences, Associate Professor
650000, Kemerovo, Sovetsky Ave., building 11, office. 2
References
1. Blood amino acids in the pathogenesis and clinic of ischemic disease / M.S. Sinkeev, Yu.I. Skvortsov, T.M. Bogdanova, K.Yu. Skvortsov // International Journal of Applied and Fundamental Research. - 2014. - No. 11(3). - P. 480-484.
2. Orlov, E.V., Arnautova M.S., Gergel N.I. Assessment of the metabolic status and cellular composition of blood in psoriasis and psoriatic arthritis // Medical almanac. - 2013. - No. 5 (29). - P.197-200.
3. Psoriasis in patients with metabolic syndrome: clinical aspects of the problem / S.G. Lykova, M.A. Morzhanaeva, O.B. Nemchaninova, E.V. Svechnikova // Clinical dermatology and venereology. - 2020. - No. 19 (2). - P. 214-222. – DOI: 10.17116/klinderma202019021214.
4. Skvortsov, Yu.I. Homocysteine as a risk factor for the development of coronary artery disease (review) / Yu. I. Skvortsov, AS Korolkova // Saratov Journal of Medical Scientific Research. - 2011. - T. 7, No. 3. - P. 619-624.
5. A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis / O. Awosika, M. G. Eleryan, M. Rengifo-Pardo [et al] // Journal of Clinical and Aesthetic Dermatology. – 2018. – No. 11(6). – P. 33-37.
6. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis / A.W. Armstrong, S.V. Voyles, E.J. Armstrong [et al] // Exp Dermatol. – 2011. – Jul. 20(7). – P. 544-9. – Doi: 10.1111/j.1600-0625.2011.01308.x.
7. Advances in understanding the immunological pathways in psoriasis / S.R. Georgescu, M. Tampa, C. Caruntu [et al] // International Journal of Molecular Sciences.– 2019. – № 20. – Р. 739. – Doi: 10.3390/ijms20030739.
8. Alterations in plasma lipid profile and cardiovascular risk indicators in clinically subgrouped psoriasis / S. Srinivas, S. Nagendra, P. Goudappala, R.T. Kashinath // International Journal of Research in Dermatology. – 2019. – V.5. – №2. – Р. 2455-4529.
9. Apolipoprotein E gene polymorphism and serum lipid profile in Saudi patients with psoriasis / F. Al Harthi, G.B. Huraib, A. Zouman [et al] // Disease Markers. – 2014. – 239645. – Doi: 10.1155/2014/239645.
10. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation/ E. Smith, K. M. Prasad, M. Butcher [et al]. – Text : electronic // Free PMC article. – 2010. – 20. – 121(15). – Р. 1746-55. – Doi: 10.1161/CIRCULATIONAHA.109.924886.
11. Boehncke, W.H. Psoriasis / W.H. Boehncke, M.P. Schön // Lancet. – 2015. – № 386. – Р. 983-994. – DOI: 10.1016/S0140-6736(14)61909-7.
12. Can microbiology afect psychiatry? A link between gut microbiota and psychiatric disorders / E. Gulas, G. Wysiadecki, D. Strzelecki, [et al] // Psychiatria Polska. – 2018. – 52. – Р. 1023-1039.
13. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia / S.E. Choon, N.M. Lai, N.A. Mohammad [et al] // International Journal of Dermatology. – 2014. – 53. – 676–684. – Doi: 10.1111/ijd.12070.
14. Current developments in the immunology of psoriasis / F. Grän, A. Kerstan, E. Serfling [et al] // Yale Journal of Biology and Medicine. – 2020. – № 93. – Р. 97–110.
15. Domagała, A. Antihistamines in the treatment of pruritus in psoriasis / A. Domagała, J. Szepietowski, A. Reich. – Text : electronic // Advances in Dermatology and Allergology. – 2017. – № 5. – Р. 457-463. – DOI: 10.5114/ada.2017.71112.
16. Dysbiosis of gut microbiota was closely associated with psoriasis / L. Huang, R. Gao, N. Yu [et al] // Sci China Life Sci. –2018. – 62(6). – Р. 807-815 https://doi.org/10.1007/s11427-018-9376-6.
17. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability / C. Erbel, T.J. Dengler, S. Wangler [et al] // Basic Res Cardiol. – 2011. –№106 (1). – Р.125-134. – Doi: 10.1007/s00395-010-0135-y.
18. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention / Younossi Z, Anstee QM, Marietti M, [et al] // Nature Reviews Gastroenterology & Hepatology. – 2018. – 15(1):11-20. – Doi: 10.1038/nrgastro.2017.109.
19. Guidelines on the treatment of psoriasis vulgaris (English version). Update / A. Nast, W.H. Boehncke, U. Mrowietz [et al] // J Dtsch Dermatol Ges. – 2012. – 10(2). – Р. 1-95. – Doi: 10.1111/j.1610-0387.2012.07919.x.
20. Gut microbial composition in patients with psoriasis / F.M. Codoñer, A. Ramírez-Bosca, E. Climent [et al] // Scientific Reports. – 2018. – 3812. – Doi: 10.1038/s41598-018-22125-y.
21. Gut microbiota dysbiosis in a cohort of patients with psoriasis / C. Hidalgo-Cantabrana, J. Gómez, S. Delgado [et al] // British Journal of Dermatology. – 2019. – 181(6). –Р. 1287-1295. – Doi: 10.1111/bjd.17931. https://doi.org/10.1111/bjd.17931.
22. Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study / A.M. Tobin, R. Hughes, T. Leong [et al] // Clin. Exp. Dermatol. – 2011. – Vol. 36. – Issue 1. – P. 19-23.
23. Hypertension and risk of psoriasis incidence: an 11-year nationwide population-based cohort study / H.N. Kim, K. Han, S.W. Song, J.H. Lee // PLoS ONE. – 2018. – e0202854. – Doi: 10.1371/journal.pone.0202854.
24. Intestinal microbiota profling and predicted metabolic dysregulation in psoriasis patients / Y.-J. Chen, Hsiu Ho, Ching-Hung Tseng [et al]. – Text : electronic // Experimental Dermatology. – 2018. – 27(12). – Р. 1336-1343. – DOI:10.1111/exd.13786.
25. Jensen, P. Psoriasis and obesity / P. Jensen, L. Skov // Dermatology. – 2016. – 232. – 633- 639. – Doi: 10.1159/000455840.
26. Leptin and the Skin: A New Frontier / B. Poeggeler, C. Schulz, M.A. Pappolla. [et al] // Experimental Dermatology. – 2010. – Vol. 19. – No. 1. – Р. 12-18. – Doi:10.1111/j.1600-0625.2009.00930.x.
27. Markers of systemic infammation in psoriasis: a systematic review and meta-analysis / E.A. Dowlatshahi, E.A. van der Voort, L.R. Arends, T. Nijsten // British Journal of Dermatology. – 2013. – 169. – 266–282. – Doi: 10.1111/bjd.12355.
28. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity / G. Musso, R. Gambino, M. Cassader, G. Pagano // Annals of Medicine. – 2011. – №43(8). – 617-49. – Doi: 10.3109/07853890.2010.518623.
29. Metabolic syndrome in patients with psoriasis / A. Wolska, M. Michalsk-Jakabus, A. Pietrzak [et al] // Polski Merkuriusz Lekarski. – 2014. – 36 (213). – Р. 215-219.
30. Methylenetetrahydrofolate Reductase C677T Gene Polymorphism as Risk Factor for Psoriasis in Saudis / G.B. Huraib, F.A. Harthi, M. Arfin [et al] // Biomark Insights. – 2019. – V. 14. – P. 1-5. – Doi: 10.1177/1177271919830973.
31. Mylonas, A. Psoriasis: Classical vs. paradoxical. Te Yin-Yang of TNF and type I interferon / A. Mylonas, C. Conrad // Front. Immunol. – 2019. – № 9. – Р. 2746.
32. NAFLD and liver transplantation: Current burden and expected challenges / R. Pais, A. S. 4th Barritt, Y. Calmus [et al] // Journal of Hepatology – 2016. – 65(6). – 1245-1257. – Doi: 10.1016/j.jhep.2016.07.033.
33. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation / A. Johnston, S. Arnadottir, J.E. Gudjonsson [et al] // British Journal of Dermatology. – 2008. – 159(2). – Р. 342-50. – Doi: 10.1111/j.1365-2133.2008.08655.x.
34. Obesity, waist circumference, weight change, and risk of incident psoriasis: prospective data from the HUNT study / I. Snekvik, C. H. Smith, TIL. Nilsen [et al] // Journal of Investigative Dermatology. – 2017. – 137. – 2484-2490. – Doi: 10.1016/j.jid.2017.07.822.
35. Overweight and weight gain predict psoriasis development in a population-based cohort / K. Danielsen, T. Wilsgaard, A.O. Olsen, A.S. Furberg // Acta Dermato-Venereologica. – 2017. – 97(3). – 332-339. – DOI: 10.2340/00015555-2530.
36. Pathogenesis of chronic plaque psoriasis and its intersection with cardiometabolic comor bidities / P. Gisondi, F. Bellinato, G. Girolomoni, C. Albanesi // Front. Pharmacol. – 2020. – Р. 11-117. – Doi: 10.3389/fphar.2020.00117.
37. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease / R. Abedini, M. Salehi, V.Lajevardi, S. Beygi // Clinical and Experimental Dermatology. – 2015. – № 40. – Р. 722-727. – Doi: 10.1111/ced.12672.
38. Prevalence of metabolic syndrome in patients with psoriasis. / I. Zindancı, O. Albayrak, M. Kavala [et al] // Scientific World Journal. – 2012. – 2012:312463. – Doi: 10.1100/2012/312463.
39. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics./ P.J. Mease, D.D. Gladman, K.A. Papp [et al] // Journal of the American Academy of Dermatology. – 2013. – № 69. – Р. 729-735.
40. Psoriasis and comorbid diseases: Implications for management / J. Takeshita, S. Grewal, S.M. Langan [et al] // Journal of the American Academy of Dermatology. – 2017. – 76. – 393- 403. – Doi: 10.1016/j.jaad.2016.07.065.
41. Psoriasis and the risk of diabetes: a prospective populationbased cohort study / M.T. Wan, D.B. Shin, R.A. Hubbard [et al] // Journal of the American Academy of Dermatology. – 2018. – 78. – 315–322. – Doi: 10.1016/j.jaad.2017.10.050.
42. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study / O. Ahlehoff, G.H. Gislason, J. Lindhardsen [et al] // PLoS ONE. – 2011. – 6. – e18125. – Doi: 10.1371/journal.pone.0018125.
43. Psoriasis is associated with a greater risk for cardiovascular procedure and surgery in patients with hypertension: A nationwide cohort study / H.Y. Chiu, W. L. Chang, M.N. Shiu [et al] // J Dermatol. – 2018. – 45(12). – 1381-1388. – Doi: 10.1111/1346-8138.14654.
44. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study / H. Yeung, J. Takeshita, N.N. Mehta [et al] // JAMA Dermatology. – 2013. – 149(10). – 1173- 9. – Doi: 10.1001/jamadermatol.2013.5015.
45. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background / G. Ganzetti, A. Campanati, E. Molinelli, A. Offidani // World J Cardiol. – 2016. – 8(2). – 120-31. – Doi: 10.4330/wjc.v8.i2.120.
46. Psoriasis: A mixed autoimmune and autoinfammatory disease / Y. Liang, M. K. Sarkar, L.C. Tsoi, J. E Gudjonsson // Curr. Opin. Immunol. – 2017. – № 49. – Р. 1-8.
47. Psoriatic disease is associated with systemic inflammation, endothelial activation, and altered haemostatic function / M.J.E. Visser, C. Venter, T J. Roberts [et al] // Scientific Reports. – 2021. – № 11. – 13043. – Doi: 10.1038/s41598-021-90684-8.
48. Psoriatic lesions are characterized by higher bacterial load and imbalance between Cutibacterium and Corynebacterium / C. Quan, X.Y. Chen, X. Li [et al] // Journal of the American Academy of Dermatology. – 2020. – 82(4). – Р. 955-961. – Doi: 10.1016/j.jaad.2019.06.024.
49. Quality of life and comorbidities in palmoplantar pustulosis—a cross-sectional study on 102 patients/ H. Trattner, S. Blüml, I. Steiner [et al].// Journal of the European Academy of Dermatology and Venereology. – 2017. – 31. – 1681- 1685. – Doi: 10.1111/jdv.14187.
50. Relationship between psoriasis and non-alcoholic fatty liver disease: Updated systematic review and adjusted meta-analysis / K. Phan, J. Onggo, O. Charlton, S. D. Smith // Australasian Journal of Dermatolog. – 2019. – 60. – e352–e355.
51. Serum Leptin, Resistin, and Adiponectin Concentrations in Psoriasis: A Meta-Analysis of Observational Studies / A. Kyriakou, A. Patsatsi, D. Sotiriadis, D.G. Goulis // Dermatology. – 2017. – 233(5). – Р. 378-389. – Doi: 10.1159/000481882.
52. Serum sphingolipid level in psoriatic patients with obesity / D. Kozłowska, E. Harasim-Symbor, H. Myśliwiec [et al] // Postȩpy Dermatologii i Alergologii. – 2019. – 36. – 714–721. Doi: 10.5114/ada.2019.91422.
53. Tcell hierarchy in the pathogenesis of psoriasis and associated cardiovascular comorbidities / F. Casciano, P.D. Pigatto, P.Secchiero [et al] // Front Immunol. – 2018. – № 9. – Р. 1390. – DOI: 10.3389/fimmu.2018.01390.
54. Te human microbiota and obesity: a literature systematic review of in vivo models and technical approaches / L. Carrera-Quintanar, D. Ortuño-Sahagún, N.N. Franco-Arroyo [et al] // International Journal of Molecular Sciences. – 2018. – 19. – 3827.
55. Te role of the microbiome in gut and joint infammation in psoriatic arthritis and spondyloarthritis / E. Gilis, C. Mortier, K. Venken [et al] // Journal of Rheumatology Supplement. – 2018. – 94. – Р. 36-39.
56. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. / M.A. Lowes, C.B. Russell, D.A. Martin [et al] //Trends Immunol. – 2013. – № 34(4). – Р. 174-81. – Doi: 10.1016/j.it.2012.11.005.
57. Thyroid dysfunction in patients with psoriasis: higher prevalence of thyroid dysfunction in patients with generalized pustular psoriasis / K. Namiki, M. Kamata, T. Shimizu [et al] // J. Dermatol. – 2020. – 47. – 133–139. – Doi: 10.1111/1346-8138.15178.
58. Trends in incidence of adult-onset psoriasis over three decades: a population-based study / M. Icen, C.S. Crowson, M.T. McEvoy [et al] // J Am Acad Dermatol. – 2009. – 60(3). – 394-401. – Doi: 10.1016/j.jaad.2008.10.062.
59. Wenk, K.S. Psoriasis and non-alcoholic fatty liver disease / K.S. Wenk, K.C. Arrington, A. Ehrlich // Journal of the European Academy of Dermatology and Venereology. – 2011. – 25. – Р. 383- 391. – DOI:10.1111/j.1468-3083.2010.03841.x.
Review
For citations:
Romanova E.L., Shabaldin A.V., Shabaldina E.V. Immune and metabolic interrelationships of psoriasis with comorbid states (literature review). Yakut Medical Journal. 2022;(3):77-81. https://doi.org/10.25789/YMJ.2022.79.20
Views:
23
Email this article 